• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


Prices delayed by at least 15 minutes | Print

Vaneck Ucits Etfs PLC VANECK GENOMICS & HEALTHCARE UCITS ETF (CURE)

Sell: $22.605|Buy: $22.885|Change: 0.18 (0.81%)

Open 

$22.715

Previous close 

$22.5625

Trade high 

$22.715

Income frequency 

-

Year low 

$17.128

Year high 

$23.36

Replication method 

Physical Full

Volume 

128

Type 

ETF

UCITS 

Yes

Dividend yield 

–

Ongoing charge 

0.35

ISIN 

IE000B9PQW54

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Share price

Asset allocation

Top 10 holdings

Holdings 23/12/2025% of assets
Regeneron Pharmaceuticals Inc8.59
Vertex Pharmaceuticals Inc8.21
Veeva Systems Inc Class A6.80
Alnylam Pharmaceuticals Inc6.36
Natera Inc6.02
DexCom Inc5.41
Illumina Inc4.91
Insulet Corp4.31
Exact Sciences Corp4.00
Guardant Health Inc3.89

Performance 30/11/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

Total return (%)
Fund+ 0.81
Category-
More...

Investment objective

The Fund’s investment objective is to replicate the price and the performance, before fees and expenses, of an index that provides exposure to the performance of a representative portfolio of companies involved in the genomic healthcare and electronic healthcare industries.

Sustainability Label

This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Learn more about SDR.

Asset class

ETF

Morningstar ratingTM

Morningstar sustainability ratingTM

Morningstar Medalist RatingTM

  Morningstar analyst document

  Morningstar report document

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.